• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Aerosol Med Pulm Drug Deliv . Minimizing Aerosol Leakage from Facemasks in the COVID-19 Pandemic

tetano

Editor, Senior Moderator
J Aerosol Med Pulm Drug Deliv


. 2023 May 12.
doi: 10.1089/jamp.2022.0036. Online ahead of print. Minimizing Aerosol Leakage from Facemasks in the COVID-19 Pandemic

Mylene G H Frankfort[SUP] 1 [/SUP], Iris Lauwers[SUP] 1 [/SUP], Emerentia M C Pruijn[SUP] 1 [/SUP], Sjoerd F Dijkstra[SUP] 1 [/SUP], Liza H G Boormans[SUP] 1 [/SUP], Nicolaas A Schouten[SUP] 2 [/SUP], Corrinus C van Donkelaar[SUP] 1 [/SUP], Hettie M Janssens[SUP] 3 [/SUP]; Team VERO



Collaborators, Affiliations
Abstract

Background: Aerosol therapies with vented facemasks are considered a risk for nosocomial transmission of viruses such as severe acute respiratory syndrome coronavirus 2. The transmission risk can be decreased by minimizing aerosol leakage and filtering the exhaled air. Objective: In this study, we determined which closed facemask designs show the least leakage. Methods: Smoke leakage was quantified during in- and exhalation in a closed system with expiration filter for three infant, six child, and six adult facemasks (three times each mask), using age-appropriate anatomical face models and breathing patterns. To assess leakage, smoke release was recorded and cumulative average pixel intensity (cAPI) was calculated. Results: In the adult group, aircushion edges resulted in less leakage than soft edges (cAPI: 407 ± 250 vs. 774 ± 152) (p = 0.004). The Intersurgical[SUP]®[/SUP] Economy 5 mask (cAPI: 146 ± 87) also released less smoke than the Intersurgical[SUP]®[/SUP] Clearlite 5 (cAPI: 748 ± 68) mask with the same size, but different geometry and edge type (p-value <0.05). Moreover, mask size had an effect, as there was a difference between Intersurgical[SUP]®[/SUP] Economy 4 (cAPI: 708 ± 346) and 5, which have the same geometry but a different size (p-value <0.05). Finally, repositioning masks increased the standard deviations. Mask leakage was not dependent on breathing patterns within the child group. Conclusions: Mask leakage can be minimized by using a closed system with a well-fitting mask that is appropriately positioned. To decrease leakage, and therewith minimize potential viral transmission, selecting a well-fitting mask with an aircushion edge is to be recommended.

Keywords: COVID-19; aerosol; aerosol therapy; facemask; leakage; nosocomial transmission.

 
Back
Top Bottom